Having one or more of these polymorphisms is associated with an increased risk of certain diseases, especially when impacted by environmental triggers such as pollution, smoking, heavy metals, and other toxins
Important: Although the study involved human subjects, its outcomes are not intended to imply any therapeutic claims
& Mraz-Gernhard, S
Existing Medicare Part D coverage for Ozempic when prescribed for Type 2 diabetes remains separate from the Medicare GLP-1 Bridge
In September 2025, the FDA and the Department of Health and Human Services (HHS) launched an enforcement initiative targeting misleading advertising in the compounded drug space
GLP-1 Receptor Agonists: A Game-Changer for Type 2 Diabetes, Obesity, and Cardiometabolic Health APRNs treating patients with type 2 diabetes, obesity, and cardiometabolic risk factors are seeing a significant shift in frontline pharmacologic care